{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'The possible answers are:', 'Not Related: There is no reasonable possibility that the event may have been caused by study', 'conduct', 'Related:', 'There is a reasonable possibility that the event may have been caused by study', 'conduct', 'A list of factors to consider when assessing the relationship of AEs or SAEs to study conduct is', 'provided in Appendix 4.', 'The investigator should justify the causality assessment of each SAE.', '9.6.', 'Safety Monitoring', 'The investigator will monitor the safety of study patient at his/her site(s) as per the requirements', 'of this protocol and consistent with current Good Clinical Practice (GCP). Any questions or', 'concerns should be discussed with the sponsor in a timely fashion. The sponsor will monitor the', 'safety data from across all study sites. The medical monitor will have primary responsibility for', 'the emerging safety profile of the compound, but will be supported by other departments', '(eg, Pharmacovigilance and Risk Management; Biostatistics and Data Management). Safety', 'monitoring will be performed on an ongoing basis (eg, individual review of SAEs) and on a', 'periodic cumulative aggregate basis.', '9.7.', 'Investigator Alert Notification', 'Regeneron (or designee) will inform all investigators participating in this clinical trial, as well as', 'in any other clinical trial using the same investigational drug, of any SAE that meets the relevant', \"requirements for expedited reporting (an AE that is serious, unexpected based on the Investigator's\", 'Brochure or this protocol, and has a reasonable suspected causal relationship to the', 'medicinal/study drug).', '10.', 'STATISTICAL PLAN', 'This section provides the basis for the statistical analysis plan (SAP) for the study. The SAP may', 'be revised during the study to accommodate amendments to the clinical study protocol and to make', 'changes to adapt to unexpected issues in study execution and data that may affect the planned', 'analyses. The final SAP will be issued before the database is locked.', 'Analysis variables are listed in Section 4.', 'Data collected regarding the impact of the COVID-19 pandemic on the patients will be', 'summarized (eg, discontinuation due to COVID-19). Any additional analyses and methods', 'required to investigate the impact of COVID-19 on the efficacy (eg, missing data due to', 'COVID-19) and safety evaluation will be specified in the SAP.', '10.1.', 'Statistical Hypothesis', 'The primary analysis of os will be performed for the following null (HO) and alternative', 'hypotheses (H1):', 'Ho: The survival curve of os for cemiplimab is the same as that for IC chemotherapy', 'Regeneron Pharmaceuticals, Inc.', 'Page 93 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'H1: The survival curve of OS for cemiplimab is superior to that for IC chemotherapy.', '10.2.', 'Justification of Sample Size', 'The primary endpoint will be overall survival among patients treated with cemiplimab versus IC', 'of chemotherapy. After progression on platinum-taxane based chemotherapy, there is no standard', 'of care. The median os has been reported in range of 6.5 months to 8.1 months in the', 'phase 2 setting (Lorusso 2010) (Miller 2008) (Schilder 2005) (Bookman 2000).', 'The primary os endpoint will be tested in patients with SCC first. If the null hypothesis is rejected', 'in SCC patients, then os will be tested in the overall population. The sample size and power are', 'calculated using East\u00ae version 6.4.1 statistical software.', 'The sponsor assumes a median OS of 7 months for SCC patients treated with IC chemotherapy', 'and a median OS of 10 months for SCC patients treated with cemiplimab. The assumptions', 'correspond to an approximately 42.8% increase in median OS and a hazard ratio (HR) of 0.7 if OS', 'is distributed exponentially in both treatment groups.', \"Two interim efficacy analyses are planned using Lan-DeMets (O'Brien-Fleming) spending\", 'function at 70% and 85% of the total OS events, respectively. A total of 340 os events in SCC', 'patients will yield approximately 90% power to detect an HR of 0.7 with an overall type I error of', '0.025 (1-sided). The details of alpha spending at interim and final analyses based on the planned', 'number of os events are provided in Section 10.5.', 'Considering the enrollment rate (2 patients/month for months 1 to 5, 9 patients/month for', 'months 6 to 16, 20 patients/month for months 17 to 23, and 22 patients/month for month 24 and', 'beyond) and 10% dropout rate per year, enrollment of 460 randomized SCC patients will yield', '340 os events for analysis of OS around 42 months after the first SCC patient is randomized.', 'At the time when 460 SCC patients are enrolled in the study, a total enrollment in the study of', 'approximately 590 patients is projected (SCC plus non-SCC). The actual number of patients to be', 'enrolled will depend on the proportion of adenocarcinoma patients in the patient population and', 'the time when Amendment 5 is implemented at each of the study sites. If the HR is 0.7, the power', 'for testing os in the overall population will be higher than 90%.', '10.3.', 'Analysis Sets', '10.3.1.', 'Efficacy Analysis Sets', 'The full analysis set (FAS) includes all randomized patients. This is the intention to treat', 'population. The FAS is based on the treatment allocated (as randomized). All efficacy endpoints', 'will be analyzed using the FAS.', '10.3.2.', 'Safety Analysis Set', 'The safety analysis set (SAF) includes all randomized patients who received any study drug. This', 'population is based on the treatment received (as treated). Treatment compliance/administration', 'and all clinical safety variables will be analyzed using the SAF.', 'Regeneron Pharmaceuticals, Inc.', 'Page 94 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}